Prosecution Insights
Prosecution Insights
13 pending office actions • 12 art units • 13 examiners • 0 of 13 (0%) have an AI response strategy ready • 18 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (8%) |
| §103 only | 2 (15%) |
| §112 only | 4 (31%) |
| Double-patenting only | 1 (8%) |
| Double-patenting + other | 3 (23%) |
| Multi-statute (no §101) | 1 (8%) |
| No statute on record | 1 (8%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DAVIS, BRIAN J | 1 | 84.8% | -4.1% |
| WILSON, MICHAEL C | 1 | 41.4% | +17.5% |
| RAHMANI, NILOOFAR | 1 | 77.5% | -3.1% |
| BELL, SARA ELIZABETH | 1 | 69.1% | +38.2% |
| SANCHEZ, JUSTIN CHRISTOPHER | 1 | 86.4% | +14.7% |
| METCALF, MATTHEW CURRAN | 1 | 40.0% | +75.0% |
| SWITZER, JULIET CAROLINE | 1 | 42.4% | +53.8% |
| LUNDE, GRACE HENRY | 1 | 63.0% | +38.9% |
| MELCHIOR, JAMES RYLAND | 1 | 62.7% | +37.7% |
| BOWLES, DAVID PAUL | 1 | 69.4% | +25.9% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18776606 | CEREBLON BINDING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | DAVIS, BRIAN J | — |
| 18572342 | PROCESSES FOR THE PREPARATION OF (S)-2-(2,6-DIOXOPIPERIDIN-3-YL)-4-((2-FLUORO-4-((3-MORPHOLINOAZETIDIN-1-YL)METHYL)BENZYL)AMINO)ISOINDOLINE-1,3-DIONE | SANCHEZ, JUSTIN CHRISTOPHER | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17620541 | AZACITIDINE IN COMBINATION WITH VENETOCLAX, GILTERITINIB, MIDOSTAURIN OR OTHER COMPOUNDS FOR TREATING LEUKEMIA OR MYELODYSPLASTIC SYNDROME | BERRY, LAYLA D | 48d |
| 18550083 | METHODS FOR USING A HYPOMETHYLATING AGENT TO TREAT DISEASES AND DISORDERS BASED ON GENE MUTATION PROFILES | SWITZER, JULIET CAROLINE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18609867 | TRANSGENIC MOUSE EXPRESSING HUMAN CEREBLON | WILSON, MICHAEL C | — |
| 18573790 | CEREBLON BINDING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BELL, SARA ELIZABETH | — |
| 18572342 | PROCESSES FOR THE PREPARATION OF (S)-2-(2,6-DIOXOPIPERIDIN-3-YL)-4-((2-FLUORO-4-((3-MORPHOLINOAZETIDIN-1-YL)METHYL)BENZYL)AMINO)ISOINDOLINE-1,3-DIONE | SANCHEZ, JUSTIN CHRISTOPHER | — |
| 18563037 | METHODS OF TREATING MULTIPLE MYELOMA USING COMBINATION THERAPY | METCALF, MATTHEW CURRAN | — |
| 18550083 | METHODS FOR USING A HYPOMETHYLATING AGENT TO TREAT DISEASES AND DISORDERS BASED ON GENE MUTATION PROFILES | SWITZER, JULIET CAROLINE | — |
| 18265235 | USES OF CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPIES IN COMBINATION WITH INHIBITORS OF INFLAMMATION-RELATED SOLUBLE FACTORS | LUNDE, GRACE HENRY | — |
| 18248205 | BISPECIFIC ANTIBODY TREATMENT OF LYMPHOID MALIGNANT NEOPLASM CONDITIONS | MELCHIOR, JAMES RYLAND | — |
| 17817777 | Composition and Methods for Selective Degradation of Engineered Proteins | BOWLES, DAVID PAUL | — |
| Art Unit | Apps |
|---|---|
| 1614 | 1 |
| 1638 | 1 |
| 1691 | 1 |
| 1625 | 1 |
| 1622 | 1 |
| 1682 | 1 |
| 1641 | 1 |
| 1644 | 1 |
| 1654 | 1 |
| 1643 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18776606 | CEREBLON BINDING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | DAVIS, BRIAN J | 1614 | §112DP | Non-Final OA | — | Pending | Jul 18, 2024 |
| 18609867 | TRANSGENIC MOUSE EXPRESSING HUMAN CEREBLON | WILSON, MICHAEL C | 1638 | §112 | Non-Final OA | — | Pending | Mar 19, 2024 |
| 18419894 | ANTIPROLIFERATIVE COMPOUNDS AND METHODS OF USE THEREOF | RAHMANI, NILOOFAR | 1691 | Other | Non-Final OA | 14d | Pending | Jan 23, 2024 |
| 18573790 | CEREBLON BINDING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BELL, SARA ELIZABETH | 1625 | §112 | Non-Final OA | — | Pending | Dec 22, 2023 |
| 18572342 | PROCESSES FOR THE PREPARATION OF (S)-2-(2,6-DIOXOPIPERIDIN-3-YL)-4-((2-FLUORO-4-((3-MORPHOLINOAZETIDIN-1-YL)METHYL)BENZYL)AMINO)ISOINDOLINE-1,3-DIONE | SANCHEZ, JUSTIN CHRISTOPHER | 1622 | §112 | Non-Final OA | — | Pending | Dec 20, 2023 |
| 18563037 | METHODS OF TREATING MULTIPLE MYELOMA USING COMBINATION THERAPY | METCALF, MATTHEW CURRAN | — | §103DP | Non-Final OA | — | Pending | Nov 21, 2023 |
| 18550083 | METHODS FOR USING A HYPOMETHYLATING AGENT TO TREAT DISEASES AND DISORDERS BASED ON GENE MUTATION PROFILES | SWITZER, JULIET CAROLINE | 1682 | §101§102§112 | Non-Final OA | — | Pending | Sep 11, 2023 |
| 18265235 | USES OF CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPIES IN COMBINATION WITH INHIBITORS OF INFLAMMATION-RELATED SOLUBLE FACTORS | LUNDE, GRACE HENRY | 1641 | §103§112DPOther | Non-Final OA | — | Pending | Jun 02, 2023 |
| 18248205 | BISPECIFIC ANTIBODY TREATMENT OF LYMPHOID MALIGNANT NEOPLASM CONDITIONS | MELCHIOR, JAMES RYLAND | 1644 | DP | Non-Final OA | — | Pending | Apr 06, 2023 |
| 17817777 | Composition and Methods for Selective Degradation of Engineered Proteins | BOWLES, DAVID PAUL | 1654 | §112 | Non-Final OA | — | Pending | Aug 05, 2022 |
| 17795829 | ANTI-CD30 ANTIBODY-DRUG CONJUGATES AND THEIR USE FOR THE TREATMENT OF NON-HODGKIN LYMPHOMA | SHUPE, ELIZABETH A | 1643 | §103 | Non-Final OA | — | Pending | Jul 27, 2022 |
| 17620541 | AZACITIDINE IN COMBINATION WITH VENETOCLAX, GILTERITINIB, MIDOSTAURIN OR OTHER COMPOUNDS FOR TREATING LEUKEMIA OR MYELODYSPLASTIC SYNDROME | BERRY, LAYLA D | 1693 | §103§112Other | Non-Final OA | 48d | Pending | Dec 17, 2021 |
| 17220377 | METHODS FOR DETERMINING DRUG EFFICACY FOR THE TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOMA, MULTIPLE MYELOMA, AND MYELOID CANCERS | GODDARD, LAURA B | 1642 | §103 | Final Rejection | — | Pending | Apr 01, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial